Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogt, L.
Right arrow Articles by de Zeeuw, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogt, L.
Right arrow Articles by de Zeeuw, D.
J Am Soc Nephrol 13:S202-S207, 2002
© 2002 American Society of Nephrology

Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics?

Liffert Vogt*, Gerjan Navis* and Dick de Zeeuw{dagger}

*Department of Internal Medicine, Division of Nephrology and {dagger}Department of Clinical Pharmacology, University Hospital, Groningen, the Netherlands.

Correspondence to Dr. Dick de Zeeuw, Department of Clinical Pharmacology, State University Groningen, Ant Deusinglaan 1. 9713 AV Groningen, the Netherlands. Phone: 31-50-363-2810; Fax: 31-50-363-2812;

ABSTRACT. Data from recent clinical trials show that lowering of BP reduces the rate of renal function loss in chronic renal disease. There is evidence supporting the assertion that BP lowering obtained by intervention in the renin-angiotensin-aldosterone system (RAAS) has an additive renoprotective effect in both diabetic and nondiabetic renal diseases. However, to dissociate BP-dependent and non–BP-dependent action of RAAS blockade, the relevant trials are in many cases flawed by design, resulting in BP differences between the comparative antihypertensive strategies. This review discusses whether the relevant literature allows for the conclusion that RAAS intervention has renoprotective effects in addition to its effects on BP. In particular, the main evidence for a specific renoprotective action of RAAS blockade is provided by its consistent antiproteinuric action, which cannot completely be attributed to the reduction in BP. Indeed, other strategies that lower proteinuria without having an antihypertensive effect, such as lowering dietary protein intake or the use of non-steroidal antiinflammatory drugs, appear to have a renoprotective effect as well. Interestingly, a consistent finding across different intervention studies is that the more proteinuria is reduced the better the kidney appears to be protected. Therefore, it is concluded that agent-characteristics of RAAS intervention (i.e., antiproteinuric properties) independently influence renal function loss in addition to its BP-lowering effect. Future studies should further explore the renoprotective benefit of non-antihypertensive intervention measures, alone and in combination with antihypertensive strategies. E-mail: d.de.zeeuw@med.rug.nl




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
L. Vogt, D. de Zeeuw, A. J. J. Woittiez, and G. Navis
Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients
Nephrol. Dial. Transplant., November 26, 2008; (2008) gfn644v1.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673